Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:20 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies
NCT01849744 · Verastem, Inc. · PHASE1 · terminated · last registry update 2017-07-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor's decision to deprioritize the program.” | – | Registry record, Verastem, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTK2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2017-07-27Also stopped (terminated): Verastem, Inc., Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine + Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine (NCT02651727)
- 2017-01-30Also stopped (terminated): Verastem, Inc., defactinib (VS-6063) + Placebo (NCT01870609)
- 2017-01-30Also stopped (terminated): Verastem, Inc., VS-5584 and VS-6063 (NCT02372227)
- 2017-01-27Also stopped (withdrawn): Verastem, Inc., VS-4718 (NCT02215629)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision